BSX Quote, Financials, Valuation and Earnings

Masimo has a net margin of 12.41% compared to Boston Scientific's net margin of -58.2%. Boston Scientific's return on equity of 8.96% beat Masimo's return on equity of -23.05%.

Boston Scientific has a consensus price target of $115.46, signalling upside risk potential of 17.22%. On the other hand Masimo has an analysts' consensus of $193.76 which suggests that it could grow by 27.17%. Given that Masimo has higher upside potential than Boston Scientific, analysts believe Masimo is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.728, which suggesting that the stock is 27.188% less volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.6B, which are larger than Masimo quarterly revenues of $600.7M. Boston Scientific's net income of $566M is higher than Masimo's net income of -$349.6M. Notably, Boston Scientific's price-to-earnings ratio is 78.80x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.74x versus 3.94x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 12.41% compared to Boston Scientific's net margin of 16.85%. Boston Scientific's return on equity of 8.96% beat Insulet's return on equity of 43.11%.

Boston Scientific has a consensus price target of $115.46, signalling upside risk potential of 17.22%. On the other hand Insulet has an analysts' consensus of $314.66 which suggests that it could grow by 22.53%. Given that Insulet has higher upside potential than Boston Scientific, analysts believe Insulet is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.728, which suggesting that the stock is 27.188% less volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Boston Scientific pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Boston Scientific quarterly revenues are $4.6B, which are larger than Insulet quarterly revenues of $597.5M. Boston Scientific's net income of $566M is higher than Insulet's net income of $100.7M. Notably, Boston Scientific's price-to-earnings ratio is 78.80x while Insulet's PE ratio is 44.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.74x versus 9.16x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

ResMed has a net margin of 12.41% compared to Boston Scientific's net margin of 26.88%. Boston Scientific's return on equity of 8.96% beat ResMed's return on equity of 25.56%.

Boston Scientific has a consensus price target of $115.46, signalling upside risk potential of 17.22%. On the other hand ResMed has an analysts' consensus of $269.42 which suggests that it could grow by 26.28%. Given that ResMed has higher upside potential than Boston Scientific, analysts believe ResMed is more attractive than Boston Scientific.

Boston Scientific has a beta of 0.728, which suggesting that the stock is 27.188% less volatile than S&P 500. In comparison ResMed has a beta of 0.755, suggesting its less volatile than the S&P 500 by 24.514%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.97% to investors and pays a quarterly dividend of $0.53 per share. Boston Scientific pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.6B, which are larger than ResMed quarterly revenues of $1.3B. Boston Scientific's net income of $566M is higher than ResMed's net income of $344.6M. Notably, Boston Scientific's price-to-earnings ratio is 78.80x while ResMed's PE ratio is 25.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.74x versus 6.39x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 12.41% compared to Boston Scientific's net margin of 8.48%. Boston Scientific's return on equity of 8.96% beat Stryker's return on equity of 15.22%.

Boston Scientific has a consensus price target of $115.46, signalling upside risk potential of 17.22%. On the other hand Stryker has an analysts' consensus of $423.40 which suggests that it could grow by 15.01%. Given that Boston Scientific has higher upside potential than Stryker, analysts believe Boston Scientific is more attractive than Stryker.

Boston Scientific has a beta of 0.728, which suggesting that the stock is 27.188% less volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Boston Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.89% to investors and pays a quarterly dividend of $0.84 per share. Boston Scientific pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Boston Scientific quarterly revenues are $4.6B, which are smaller than Stryker quarterly revenues of $6.4B. Boston Scientific's net income of $566M is higher than Stryker's net income of $546M. Notably, Boston Scientific's price-to-earnings ratio is 78.80x while Stryker's PE ratio is 47.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Boston Scientific is 8.74x versus 6.28x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.